These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 17081963

  • 1. Jumpstarting research into neglected diseases.
    Leslie M.
    Cell; 2006 Nov 03; 127(3):443-5. PubMed ID: 17081963
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.
    Moran M.
    PLoS Med; 2005 Sep 03; 2(9):e302. PubMed ID: 16138789
    [Abstract] [Full Text] [Related]

  • 4. The European rare diseases therapeutic initiative.
    Fischer A, Borensztein P, Roussel C.
    PLoS Med; 2005 Sep 03; 2(9):e243. PubMed ID: 16104832
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ.
    Clin Ther; 2010 Aug 03; 32(9):1651-61. PubMed ID: 20974323
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC, He L, He G, He Y.
    J Public Health Policy; 2010 Dec 03; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [Abstract] [Full Text] [Related]

  • 11. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G.
    Wall St J (East Ed); 2005 Nov 15; ():A1, A18. PubMed ID: 16502531
    [No Abstract] [Full Text] [Related]

  • 12. "Creating hope" and other incentives for drug development for children.
    Connor E, Cure P.
    Sci Transl Med; 2011 Jan 19; 3(66):66cm1. PubMed ID: 21248312
    [Abstract] [Full Text] [Related]

  • 13. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE.
    Drug Discov Today; 2011 Dec 19; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract] [Full Text] [Related]

  • 14. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE, van Weely S, Büller HA, Leufkens HG, de Vrueh RL.
    Drug Discov Today; 2009 Dec 19; 14(23-24):1166-73. PubMed ID: 19818412
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. R&D policy, agency costs and innovation in personalized medicine.
    Yin W.
    J Health Econ; 2009 Sep 19; 28(5):950-62. PubMed ID: 19671480
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.